CCM vs MLAB

For growth investors, Mesa Laboratories, Inc.

(MLAB) is the stronger pick with 11. 5% revenue growth year-over-year, versus -28. 6% for Concord Medical Services Holdings Limited (CCM). Analysts rate Concord Medical Services Holdings Limited (CCM) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Mesa Laboratories, Inc.

(MLAB) delivered a total return of -56. 5%, compared to -84. 9% for Concord Medical Services Holdings Limited (CCM). Over 10 years, the gap is even starker: MLAB returned +3. 1% versus CCM's -87. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Concord Medical Services Holdings Limited (CCM) is the lower-risk stock at 0.

51β versus Mesa Laboratories, Inc. 's 1. 75β — meaning MLAB is approximately 246% more volatile than CCM relative to the S&P 500. On balance sheet safety, Mesa Laboratories, Inc. (MLAB) carries a lower debt/equity ratio of 114% versus 2% for Concord Medical Services Holdings Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Mesa Laboratories, Inc.

(MLAB) is pulling ahead at 11. 5% versus -28. 6% for Concord Medical Services Holdings Limited (CCM). On earnings-per-share growth, the picture is similar: Mesa Laboratories, Inc. grew EPS 99. 2% year-over-year, compared to -3. 6% for Concord Medical Services Holdings Limited. Over a 3-year CAGR, MLAB leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Mesa Laboratories, Inc.

(MLAB) is the more profitable company, earning -0. 8% net margin versus -80. 3% for Concord Medical Services Holdings Limited — meaning it keeps -0. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MLAB leads at 6. 8% versus -138. 6% for CCM. At the gross margin level — before operating expenses — MLAB leads at 62. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Concord Medical Services Holdings Limited (CCM) trades at 1.

4x forward P/E versus 11. 5x for Mesa Laboratories, Inc. — 10. 2x cheaper on a one-year earnings basis.

In this comparison, MLAB (0.

6% yield) pays a dividend. CCM does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Concord Medical Services Holdings Limited (CCM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

51)). Mesa Laboratories, Inc. (MLAB) carries a higher beta of 1. 75 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CCM: -87. 5%, MLAB: +3. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CCM (Healthcare) and MLAB (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

MLAB pays a dividend while CCM does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.